on EUROMEDIS GROUPE (EPA:ALEMG)
Euromedis Laboratories: 2025 Annual Results
On April 24, 2026, the Board of Directors of Euromedis approved the accounts for the year 2025. The year was marked by significant events, including the application of a new accounting regulation without major impact.
The accounts include two non-recurring items: a cost of €0.5 million related to procedures affecting subsidiaries and a provision of €1.15 million for an ongoing tax audit, which the company disputes.
In 2025, revenue increased by 13%, reaching €40.8 million. Gross margin improved by 28%, thanks to better logistics and a favorable exchange rate environment. EBITDA turned positive at €1.2 million.
For 2026, the group plans to maintain this momentum despite geopolitical uncertainties, particularly in the Middle East.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all EUROMEDIS GROUPE news